Today: 29 April 2026
Boeing stock dips after hours as Pentagon awards $2.7 billion Apache support contract
31 December 2025
2 mins read

Boeing stock dips after hours as Pentagon awards $2.7 billion Apache support contract

NEW YORK, December 31, 2025, 5:20 PM ET — After-hours

  • Boeing shares fell about 0.6% in after-hours trading, tracking a weaker finish for U.S. stocks.
  • A Pentagon contract notice showed Boeing won a $2.73 billion Army award for Apache helicopter post-production support.
  • Investors are watching whether defense work can underpin cash flow as Boeing navigates tight FAA oversight of its commercial jet output.

Boeing shares slipped in after-hours trading on Wednesday after a Pentagon contracts notice showed the company won an Army award worth about $2.7 billion tied to Apache helicopter support. Boeing stock was down about 0.6% at $217.12.

The latest award matters because Boeing is leaning on steadier defense work to balance a still-scrutinized commercial jet business. With markets heading into a holiday break, investors have been quick to latch onto any sign of durable revenue and cash generation going into 2026.

A Reuters Breakingviews column noted that roughly a third of Boeing’s revenue comes from its defense, space and security segment, which depends on government contracts. It also pointed to Wall Street price targets implying a 38% rise over the next 12 months, based on Visible Alpha data as of late November.

The Army notice listed the Boeing award at $2,728,234,918 and described it as a firm-fixed-price contract — meaning the price is set and Boeing typically bears more of the cost overrun risk. The work locations and funding will be set with each order under the contract, with an estimated completion date of Dec. 31, 2030.

The Apache support award landed two days after the Pentagon announced an $8.6 billion Boeing contract for the F-15 Israel Program, including 25 new F-15IA jets with an option for 25 more. The Pentagon said contract work would be performed in St. Louis and was expected to be completed by Dec. 31, 2035.

Boeing stock traded between $216.14 and $219.50 during the regular session, LSEG data showed. It closed the year-end session as U.S. indexes fell, with the Dow down 0.63% and the S&P 500 down 0.74%.

Thin holiday volumes helped amplify moves across the tape. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

Boeing’s defense wins also keep the company in the center of Washington’s industrial policy debate. The Breakingviews column argued a U.S. government investment in Boeing would fit a broader push toward “state capitalism,” given Boeing’s role as a major military supplier and exporter. Reuters

At the same time, the commercial side remains a key swing factor for equity investors. Breakingviews said the Federal Aviation Administration limits how many 737 MAX planes Boeing can make and can shape how much autonomy the company has in conducting inspections — oversight that investors see as a gatekeeper for any production rebound.

Competitive pressures remain in the background. Boeing and Airbus dominate large commercial jetmaking — a duopoly, meaning a market led by two players — while Breakingviews highlighted state-backed rivals, noting that the German, French and Spanish governments collectively own about a quarter of Airbus.

Traders now look to the next full session for follow-through, after U.S. stock markets close Thursday for New Year’s Day and reopen Friday. Any fresh Pentagon awards, FAA signals, or company updates on inspections and production will likely be the next headline catalysts for Boeing shares.

For now, Boeing ended the year just below the $220 level it tested during the session, leaving investors to weigh whether the latest defense contract flow can offset lingering uncertainty around commercial output in early 2026.

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Cambridge, Massachusetts, April 29, 2026, 09:04 EDT Biogen Inc. cut its full-year profit outlook on Wednesday, taking some shine off a first-quarter earnings beat driven by stronger sales of its Alzheimer’s drug Leqembi and newer rare-disease medicines. The Cambridge, Massachusetts-based drugmaker now expects 2026 adjusted earnings of $14.25 to $15.25 a share, down $1 at both ends of its prior range. Biogen said the cut reflects acquired in-process research and development charges, meaning costs tied to buying or licensing drug programs that are still being developed and have not yet become commercial products. The revision matters because Biogen is trying
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
AppLovin stock falls nearly 3% into year-end as tech slide hits high-growth names
Previous Story

AppLovin stock falls nearly 3% into year-end as tech slide hits high-growth names

Caterpillar stock ends 2025 lower — what investors are watching for CAT in January
Next Story

Caterpillar stock ends 2025 lower — what investors are watching for CAT in January

Go toTop